Financials
Financial year 2025
Worth noting
- A loss two years in a row.
- The team shrank two years in a row.
Gross margin
€ -140,092
▼ 338% vs 2024
Profit
Caution€ -108,262
▲ 64% vs 2024
Debts
Low€ 3.1 million
RXW Group from Sint-Martens-Latem, company number BE0505854901, closed financial year 2025 with a result of € -108,262 after tax. For that financial year RXW Group recorded a gross margin of € -140,092 and equity of € 4.4 million. Compared with financial year 2024, the result moved from € -304,458 to € -108,262. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.
What happened at RXW Group?
What happened at RXW Group in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- CRJ Finance BV stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 108,262. filed late Source: NBB ↗
- Thierry Vandenbergh stepped down as director. NBB
- Les Amis De Norbert BV stepped down as director. NBB
- ConsolID BV stepped down as director. NBB
- PHiDeX Inc. BV stepped down as director. NBB
- Nesch Invest BV stepped down as director. NBB
- CRJ Finance BV became a director. NBB
In short
From € 138,211 profit in 2021 to € 108,262 loss in 2025.
Paid € 44,883 in corporate taxes since 2021.
Best year ever: 2021, with € 138,211 profit.
On average € 126,700 of value added per employee in 2021.
A new publication or filing at RXW Group? We notify you, reason included.
Follow RXW GroupNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 100% of EYTELIA, 100% of CFG PHARMA and 100% of SIL'INNOV itself.
Directors
According to the 2025 annual accounts
since 2019 · until 2025
Director · represented by Martin Devos
since 2019 · until 2025
Director · represented by Dries Moens
Also active at: CUBX Properties, ACTIVIOR, PremiumStock +9 more
since 2019 · until 2025
Managing director · represented by Christiaan Willaert
Also active at: CFG Pharma, Nesch Invest
since 2021 · until 2027
Director · represented by Johan Lamoot
since 2019 · until 2025
Director · represented by Geert Van Gijseghem
Also active at: MAB Consult Europe, EPM Pharma Invest, PhiDeX Inc. +6 more
since 2019 · until 2025
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 180 box 3
9830 Sint-Martens-Latem
Rue de Liège(CO) 2
6180 Courcelles
Active since 1 January 2017
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 16 companies are registered at this address.
ADMISOL
€ 1.6 million gross margin · 2025
MAB Consult Europe same network
€ -849 gross margin · 2025
CASA GRANDE
€ 373,195 gross margin · 2025
EPM Pharma Invest same network
€ -66 gross margin · 2025
LES AMIS DE NORBERT same network
€ -9,140 gross margin · 2025
+11 more
Details
- Company number
- 0505.854.901
- VAT number
- BE 0505.854.901
- Registered office
- Kortrijksesteenweg 180 bus 3, 9830 Sint-Martens-Latem
- Names & denominations
- RXW Group
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 November 2014
- Peppol
- Active · Active since 30 Jan 2025
- Activities · NACE
Activiteiten van holdings
Holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering